VarmX Raises €32 Million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulants

VarmX Raises €32 Million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulants

Business Wire

Published

LEIDEN, The Netherlands--(BUSINESS WIRE)--VarmX announces the completion of a €32 million Series B financing round to develop innovative approaches for the reversal of anticoagulation.

Full Article